EGF and non-small cell lung carcinoma: Patients with PD1-naïve, pre-treated NSCLC were enrolled in a phase II trial and received CIMAvax-EGF every 2 weeks, receiving four doses in combination with nivolumab, followed by monthly maintenance with CIMAvax-EGF and nivolumab every 2 weeks [29].